The first patient to take part in a clinical trial sponsored by University College London (UCL) using deep brain stimulation (DBS) to treat epilepsy has experienced an 80% reduction in daytime seizures.
The UK teenager is enrolled in the CADET pilot (Children’s Adaptive Deep brain stimulation for Epilepsy Trial), which is using Amber Therapeutics’ DBS device called the Picostim, with a software called DyNeuMo-1.
The device is mounted onto the skull and is attached to electrodes deep in the brain to reduce seizure activity.
The Picostim DyNeuMo neuromodulation therapy platform was developed by UK-based Bioinduction, but Amber Therapeutics inherited the device following a September 2023 acquisition of the company.
Martin Tisdall, honorary associate professor at UCL, said: “Deep brain stimulation brings us closer than ever before to stopping epileptic seizures for patients who have very limited effective treatment options.
22 patients are expected to take part in the full trial, which is being funded by the GOSH Charity and LifeArc. Credit: SewCreamStudio via Shutterstock.
The first patient to take part in a clinical trial sponsored by University College London (UCL) using deep brain stimulation (DBS) to treat epilepsy has experienced an 80% reduction in daytime seizures.
The UK teenager is enrolled in the CADET pilot (Children’s Adaptive Deep brain stimulation for Epilepsy Trial), which is using Amber Therapeutics’ DBS device called the Picostim, with a software called DyNeuMo-1.
Oran, who suffers from a rare epilepsy syndrome called Lennox-Gastaut, was the first child in the UK to have the device implanted at Great Ormond Street Hospital (GOSH) in October 2023, when he was 12 years old. The device is mounted onto the skull and is attached to electrodes deep in the brain to reduce seizure activity.
Picostim is mounted on the skull instead of traditional DBS devices which are mounted on the chest. This makes the device more suitable for growing children as the wires are less likely to break and erode. Additionally, it doesn’t require surgery to replace it every three to five years because it’s rechargeable through wearable headphones.
Three more patients with Lennox-Gastaut syndrome will now be recruited into the CADET pilot, which is funded by the Royal Academy of Engineering. Study sponsor UCL says that 22 patients are expected to take part in the full trial, which is being funded by the GOSH Charity and LifeArc.
The Picostim DyNeuMo neuromodulation therapy platform was developed by UK-based Bioinduction, but Amber Therapeutics inherited the device following a September 2023 acquisition of the company.
How well do you really know your competitors? Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge. View profiles in store Company Profile – free sample Thank you! Your download email will arrive shortly Not ready to buy yet? Download a free sample We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form By GlobalData Submit Country * UK USA Afghanistan Åland Islands Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bonaire, Sint Eustatius and Saba Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos Islands Colombia Comoros Congo Democratic Republic of the Congo Cook Islands Costa Rica Côte d"Ivoire Croatia Cuba Curaçao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and McDonald Islands Holy See Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati North Korea South Korea Kuwait Kyrgyzstan Lao Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macedonia, The Former Yugoslav Republic of Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia Moldova Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Northern Mariana Islands Norway Oman Pakistan Palau Palestinian Territory Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Réunion Romania Russian Federation Rwanda Saint Helena, Ascension and Tristan da Cunha Saint Kitts and Nevis Saint Lucia Saint Pierre and Miquelon Saint Vincent and The Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and The South Sandwich Islands Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syrian Arab Republic Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates US Minor Outlying Islands Uruguay Uzbekistan Vanuatu Venezuela Vietnam British Virgin Islands US Virgin Islands Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe Kosovo Industry * Academia & Education Aerospace, Defense & Security Agriculture Asset Management Automotive Banking & Payments Chemicals Construction Consumer Foodservice Government, trade bodies and NGOs Health & Fitness Hospitals & Healthcare HR, Staffing & Recruitment Insurance Investment Banking Legal Services Management Consulting Marketing & Advertising Media & Publishing Medical Devices Mining Oil & Gas Packaging Pharmaceuticals Power & Utilities Private Equity Real Estate Retail Sport Technology Telecom Transportation & Logistics Travel, Tourism & Hospitality Venture Capital Tick here to opt out of curated industry news, reports, and event updates from Clinical Trials Arena. Submit and download Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
Martin Tisdall, honorary associate professor at UCL, said: “Deep brain stimulation brings us closer than ever before to stopping epileptic seizures for patients who have very limited effective treatment options. We are excited to build the evidence base to demonstrate the ability of deep brain stimulation to treat paediatric epilepsy and hope in years to come it will be a standard treatment we can offer.”
It’s not just epilepsy that can be targeted by DBS devices. Earlier this week, Boston Scientific secured a CE mark for its Vercise Neural Navigator 5 Software, designed to be used as part of the company’s DBS system for the treatment of Parkinson’s disease.
According to a report on GlobalData’s Medical Intelligence Center, the neuromodulation devices market in the UK will be worth $234m (£184.8m) by 2030.
GlobalData is the parent company of Clinical Trials Arena.
